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ABSTRACT
Background: Although mucoid impaction of the bronchi (MIB) is a well-known manifestation in allergic bron-
chopulmonary mycosis (ABPM), when unknown samples or plural eumycetes are cultured from bronchial mate-
rials, several problems are encountered which can affect the definitive diagnostic process or successful treat-
ment.
Case Summary: The definitive diagnostic process of two patients [a 58-(Case 1) and a 70-(Case 2) year-old
female] with MIB was: 1) to identify the existence of any allergic respiratory disorder, 2) to detect the fungi ob-
tained from bronchial materials, with use of the 28S rDNA sequencing and analysis, 3) to investigate whether
the detected fungus was a probable etiologic antigen, and 4) to make the final diagnosis based on the results of
the inhalation examinations using the antigenic solution of the fungi. As a treatment strategy, bronchial toilet
and low dose itraconazole therapy were planned according to the clinical manifestations of each patient.
Discussion: The two patients with MIB were successfully diagnosed as ABPM caused by Schizophyllum
commune (Sc-ABPM) accompanied with hyperattenuating mucoid impaction. The reliability of some aller-
gological makers as a substitution for the bronchoprovocation test should be clarified in near future. Clinical
manifestations demonstrated in our cases suggested that the allergic reaction such as eosinophilic bronchoal-
veolitis spreading around the mucus plug was a primary lesion underlying the Sc-ABPM. The success of the
treatment for Sc-ABPM will be achieved by the strategy targeting to fundamental condition and by the control of
the disease recurrence by means of effective environmental management.
KEY WORDS
allergic bronchopulmonary mycosis, hyperattenuating mucoid impaction, mucoid impaction of the bronchi,
Schizophyllum commune, specific-IgE for Schizophyllum commune
ABBREVIATIONS
MIB, mucoid impaction of the bronchi; ABPM, allergic bronchopulmonary mycosis; ABPA, allergic bronchopul-
monary aspergillosis; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; BALF, bron-
choalveolar lavage fluid; ITCZ, itraconazole.
INTRODUCTION
When allergic bronchopulmonary mycosis (ABPM)1
is considered in a patient with mucoid impaction of
the bronchi (MIB),2 the clinical diagnosis is often
based on the diagnostic criteria for allergic bron-
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Fig.　1　a: Mediastinal window of computed tomography of the chest show-
ing high attenuation bronchial mucous pluggings in the left B8 bronchus in 
Case 1. b: Computed tomography of the chest showing mucus plugs in the 
left B8-10 bronchi surrounded by small granular shadows in the left S9.
a b
chopulmonary aspergillosis (ABPA)3 as described by
Rosenberg. It is true that the accuracy of molecular
analyses for identifying environmental fungi has
greatly improved in recent years, but when unknown
samples or plural eumycetes are cultured from bron-
chial materials of MIB patients, meticulous attention
to details will be necessary to diagnose ABPM ac-
cording to the diagnostic criteria of ABPA.4
We have proposed a diagnostic process of allergic
fungal respiratory disease5 consisting of the following
4 steps; 1) to try to identify the existence of any aller-
gic respiratory disorder (eosinophilia in the sputum
andor BALF, tissue eosinophilia in the specimen of
transbronchial lung biopsy), 2) to detect and identify
the fungi obtained from bronchial materials (espe-
cially BALF or mucous plug [repeated samples of
sputum are substituted when previous two materials
are not available]), with use of the 28S rDNA (D1
D2) sequencing and analysis, 3) to investigate
whether the detected fungus was a probable etiologic
antigen; skin reaction andor precipitating antibody
andor the fungus specific IgE, and 4) to make the fi-
nal diagnosis based on the results of the inhalation
examinations using the antigenic solution of the
fungi.
This diagnostic process allowed us to overcome
the difficulties and the problems associated with diag-
nosing ABPM based on the diagnostic criteria for
ABPA, and the two patients with MIB were success-
fully diagnosed as ABPM caused by Schizophyllum
commune (S. commune) (Sc-ABPM). Although the ef-
ficacy of antifungal therapy in some ABPA patients
has already been reported,6 the therapeutic strategy
for Sc-ABPM has not been still established. Based on
the clinical manifestations which were demonstrated
in our present cases, we hypothesized the primary le-
sion responsible for Sc-ABPM, and subsequently ad-
junctive therapies such as bronchoscopic suctioning
and flushing2 or the itraconazole (ITCZ) therapy7
were planned. The recurrence of the disease experi-
enced in our case of Sc-ABPM suggested both the
importance of evaluating the existence of environ-
mental fungi and the necessity for improved environ-
mental management.
CLINICAL SUMMARY
CASE REPORT 1
A 58-year-old female patient was admitted to our hos-
pital on January 4, 2007 for investigation of a produc-
tive cough and abnormal pulmonary infiltrates. Symp-
toms of cough and sputum developed in December
2006 and had not since improved. Physical examina-
tion revealed the following: her temperature was
36.2℃, and her heart rate 98 beats per minute. Aus-
cultation did not reveal any abnormalities, such as
wheezes or rhonchi.
Laboratory studies showed a white blood cell count
of 4,900 per μl with 20.9% eosinophils. No inflamma-
tory reactions were observed as assessed by C-
reactive protein level and erythrocyte sedimentation
rate (ESR). Radioimmunosorbent tests revealed ele-
vated total IgE levels in the serum (805 Uml), and
the results of radioallergosorbent test for specific IgE
antibodies against Aspergillus, Penicillium, Candida,
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Table　1　Characteristics of the two patients with ABPM caused by Schizophyllum commune
Case 1 Rosenberg Case 2 Rosenberg
Age 58 70
Gender F F
The existence of eosinophilic involve-
ment
Sputum (%) 89 77
Mucus plug Positive Positive
TBBB Positive Positive
The fungi obtained from bronchial ma-
terials
Sputum S. commune Yes B. adusta No
Mucus plug S. commune, C. albicans
BAL S. commune
Immediate skin reactivity to S.commune 9 × 9/27 × 29 Yes 16 × 20/48 × 60 Yes
Arthus reactivity (late skin reactivity) to S.commune (-) No 20 × 20/80 × 150 Yes
The fungus specifi c IgE (kIU/L) 1.34 3.37
The fungus specifi c IgG (mgA/L) 10.7 2.84
The bronchoprovocation test Positive S. commune S. commune
Negative A.niger B. adusta, Candida
Asthma (-) No (-) No
Peripheral blood eosinophilia (%) 20.9 Yes 9.4 Yes
Precipitating antibodies against S.commune antigen (-) No
Elevated serum immunogloblin E concentrations (IU/
ml)
805 Yes 787 Yes
History of pulmonary infi ltrates (transient or fi xed) MIB, HAM Yes HAM, Consolidation Yes
Central bronchiectasis (-) No (+) Yes
History of expectration of brown plugs or fl ecks (-) No (+) Yes
Fever (-) (+)
Environmental provocation tests (-) (+)
Relapse (-) (+)
Survay of environmental fungi Not paticular S. commune
Forced vital capacity (FVC) (L) 2.84 (108.0%)   2.56 (113.3%)
Forced expiratory volume in 1 second (FEV1) (L) 2.31 (100.0%) 1.90 L (113.8%)
FEV1/FVC ratio 81.3% 74.2%
PC20 (mg/ml) >20 2.02
and Alternaria were 1.08, 2.49, 0.91, and 0.48 (UA
mL), respectively. Differential cell analysis of sputum
revealed marked eosinophilia (4% alveolar macro-
phages, 7% neutrophils, and 89% eosinophils).
Chest radiographs taken upon admission showed
consolidation on the left lung field. Mediastinal win-
dow of computed tomography of the chest showed
high attenuation bronchial mucous plugs8 in the left
B8 bronchus (Fig. 1a), and a corresponding section
on the lung window demonstrated the mucus-filled di-
lated bronchi and extensive bronchiectasis (Fig. 1b).
Bronchoscopy revealed thick green mucous plugs
in the left B9a and B10. Histological examination of
transbronchial bronchial biopsy specimens obtained
from the bifurcation of the left B8 and the left B9
showed infiltration of eosinophils into the wall of the
bronchial mucosa but no fungal spores or hyphae. By
using 28S rDNA (D1D2) sequencing and analyses,
the basidiomycetous fungus obtained from the spu-
tum samples and bronchial samples of this patient
were both identified as S. commune.
The immediate (15 min) skin reaction was 9 × 9
27 × 29 for S. commune, and 10 × 836 × 28 for Asper-
gillus niger (A. niger); The results were judged to be
positive because of the longer axis of the flare beyond
9 mm. The serum anti-fungus antibody titers meas-
ured by the Ouchterlony method were negative for
both fungi. The specific IgG and IgE levels for S. com-
mune measured by the Phadia CAP system (Phadia
Ltd, Uppsala, Sweden)9 were revealed to be positive
10.7 (>2.00) mgAL and 1.34 (>0.35) kIUL respec-
tively.
Five days after the admission the patient’s cough-
ing gradually improved. After suction removal of mu-
cus plugs with a bronchoscope, the patient’s chest ra-
diograph showed further resolution.
The results of a pulmonary function test using the
Collins DS system10 and the provocative concentra-
tion of methacholine11 that caused a 20% decrease
from the baseline FEV1 (PC20) are summarized in
Table 1.
The bronchoprovocation test using A. niger antigen
was negative; however, the test using S. commune an-
tigen was graded as positive due to the development
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Fig.　2　a: Chest radiographs taken upon admission showing consolidation on the right 
lung fi eld in Case 2. b: Mediastinal window of computed tomography of the chest showing 
hyperattenuating mucoid impaction in the right S3.
a b
of a coughing attack and a ticklish throat, significant
decrease in PaO2 (from 97.4 to 84.1 mmHg), and in-
crease in the serum CRP (from 0.82 to 2.12 mgdl)
on the day following the provocation. These symp-
toms spontaneously disappeared within 3 days after
the challenge.
She experienced no recrudescence after returning
home after environmental exposure, and a fungal cul-
ture obtained from the floor of the patient’s bedroom
yielded no significant colonies. Subsequently the pa-
tient’s coughing had subsided on February 22 and S.
commune had disappeared from her sputum without
any need for the administration of antifungal drugs.
The patient has since been healthy without any recur-
rence of the symptoms during the following 4 years
without any need for the use of corticosteroids.
CASE REPORT 2
A 70-year-old female patient was admitted to our hos-
pital on March 28, 2009 for the investigation of a pro-
ductive cough, high fever, general malaise, and ab-
normal pulmonary infiltrates. The mucus plug pro-
duction developed in January 2009 and had not im-
proved. Physical examination revealed a body tem-
perature of 38.0℃ and a heart rate of 100 beats per
minute. Auscultation did not reveal any abnormalities
such as wheezes or rhonchi.
Laboratory tests revealed a white blood cell count
of 14,500 per μl with 9.4% eosinophils. CRP increased
to 17.3 mgdl. A radioimmunosorbent test revealed
an elevated total IgE level (787 Uml), and the ra-
dioallergosorbent test for specific IgE antibodies
against Aspergillus, Penicillium, Candida, and Alter-
naria were 1.31, 1.83, 1.00, and 0.57 (UAmL), re-
spectively. A differential cell analysis of sputum re-
vealed marked eosinophilia (1% alveolar macro-
phages, 22% neutrophils, and 77% eosinophils).
Chest radiographs taken upon admission (Fig. 2a)
showed consolidation on the right lung field. Medi-
astinal window of computed tomography of the chest
showed hyperattenuating mucoid impaction8 in the
right S3 (Fig. 2b).
Although bronchoscopy did not disclose mucous
plugs in the right upper lobe bronchi, many small
mucous plugs were gathered by bronchial washing.
Histological examinations of the mucous plug sam-
ples revealed numerous eosinophils. Transbronchial
lung biopsy specimens obtained from the right S2
showed intraluminal exudation and septal infiltration
of eosinophils. Molecular analysis revealed that the
sputum culture samples were Bjerkandera adusta (B.
adusta) and the mucous plugs were S. commune and
Candida albicans (C. albicans).
The immediate skin reaction was 12 × 1028 × 34
for B. adusta, 10 × 1018 × 16 for C. albicans, 6 × 68 ×
6 for A. fumigatus and 16 × 2048 × 60 for S. com-
mune. The late (8 hr) skin reactions were positive for
only S. commune (20 × 2080 × 150). Additional ex-
amination of the immediate skin reaction for S. com-
mune was 18 × 1455 × 40, 14 × 1237 × 40, 10 × 10
29 × 28, 8 × 824 × 22, 6 × 616 × 12, and 2 × 20 × 0 at
concentrations of 10-3, 10-4, 10-5, 10-6, and 10-7 mgml,
respectively. And the specific IgG and IgE levels for
S. commune was revealed to be positive (2.84 mgAL
and 3.37 kIUL respectively).
The patient was initially treated with antibiotics
(Sultamicillin tosilate, 3.0 gday and Ciprofloxacin hy-
drochloride, 600 mgday), although marked eosino-
philia (21.7%) was present in the peripheral blood. As
a result, the antibiotics were discontinued but the pa-
tient’s cough and high fever gradually subsided and a
chest radiograph revealed further improvement in six
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days following the hospital admission.
Environmental causes were investigated since the
patient experienced a recrudescence a day after first
returning home on April 21, specifically the recur-
rence of dry cough, high fever (38.4℃), increase in
the serum CRP (from 0.1 to 4.2 mgdl), decrease in
PaO2 value (from 106 to 88.0 mmHg) and decrease in
eosinophil count in the peripheral blood (13.3 to 3.0%
(651.7 to 243.0 per μl)). The patient’s coughing and
high fever had subsided, and was accompanied by an
increase in blood eosinophils (9.2% (432.4 per μl) on
April 27 without any therapy).
Though the bronchoprovocation test using B.
adusta antigen and C. albicans were both negative,
the results of the bronchoprovocation test using S.
commune at the concentration of 10-7 mgml was
graded as positive due to the development of a cough-
ing attack and a febrile 8 hrs after the inhalation, sig-
nificant decrease in PaO2 (from 101.3 to 86.7 mmHg),
and increase in the serum CRP (from 0.07 to 4.16
mgdl) on a day following the provocation. These
symptoms spontaneously disappeared within 3 days
after the challenge.
As an experimental treatment to prevent hypersen-
sitivity to environmental fungi, we prescribed a low
dose of ITCZ7 to the patient one day before the 2nd
trial of returning home, and the patient did not expe-
rience any recrudescence at this time. Thereafter,
based on the successful results of the environmental
exposure test, the patient was finally discharged from
the hospital on May 7. After being discharged from
the hospital, the patient was maintained on ITCZ
syrup 50 mgday, which was gradually reduced to
alternate-day dosage during a 3-month period and
thereafter this medication was terminated without
any further need for the administration of corticoster-
oids.
The patient experienced recrudescence of a pro-
ductive cough on July 1, 2010. She was afebrile with
no significant laboratory findings. Petri dishes with
Sabouraud’s agar medium were exposed for two
hours on the floor of the patient’s bedroom, and S.
commune colonized these plates. Because computed
tomography of the patient’s chest showed mucoid im-
paction in the right S3, she underwent bronchoscopic
suctioning and flushing on August 17, and has been
healthy for the 6 months following the procedure.
PATHOLOGICAL FINDINGS AND DISCUS-
SION
Invasive infection by basidiomycetous fungi is rare
and much of the literature reports have suggested
the possible role of basidiospores as airborne aller-
gens.12-14 And the reports on ABPM or Allergic fun-
gal sinusitis due to S. commune have been increasing
in incidence.15-17
The consistency with the Rosenberg criteria was
initially evaluated in the two patients with MIB who
were successfully diagnosed to have Sc-ABPM using
a diagnostic process that we previously proposed for
allergic fungal respiratory disease.5
Four of 7 primary characteristics and 1 of 3 secon-
dary criteria in the Rosenberg criteria were fulfilled in
Case 1. Five of 7 primary and 2 of 3 secondary charac-
teristics were filled in Case 2 (Table 1). Therefore,
the probable diagnosis of ABPM due to S. commune
could be determined according to the Rosenberg cri-
teria in both cases. On the other hand, in Case 2, plu-
ral eumycetes were cultured from bronchial materi-
als, this case also met the criteria of allergic bron-
chopulmonary candidiasis18; such as C. albicans in
sputum, immediate skin reactivity to the C. albicans
antigen, precipitating antibodies against C. albicans
antigen.
The well-known data, such as peripheral blood
eosinophilia and elevated serum IgE concentrations
included in the Rosenberg criteria,3 indicate that
there is an allergological factor involved in the indi-
vidual’s condition, but are not sufficient to demon-
strate the presence of an allergic reaction against the
identified fungi.
Although positive result of immediate skin reactiv-
ity for the specific fungus is an important allergologi-
cal marker, our preliminary study revealed that the
positive ratio of the immediate skin reaction for S.
commune was 5.5%, 5.6%, 21.4%, and 28.3% in healthy
volunteers, mild asthmatics, moderate asthmatics,
and severe asthmatics, respectively (unpublished
data). Furthermore the positive result of the titer of
specific IgG for S. commune had been considered to
be an allergological marker of hypersensitivity to the
fungus, but it was also revealed to be positive in the
case of MIB which was independent of hypersensitiv-
ity reactions caused by S. commune in association
with bronchiectasis.19
Therefore, even if S. commune was considered as a
probable causative antigen on basis of allergological
studies such as the immediate skin reaction and the
serum anti-fungus antibody titers, it was difficult to
make a definitive diagnosis of Sc-ABPM without ac-
complishing the fourth step in the definitive diagnos-
tic process. We carried out the bronchoprovocation in
accordance with the standardized method for antigen
inhalation tests on bronchial asthma and hypersensi-
tive pneumonitis described in 1982.20
Because a severe dual repose to A. fumigatus in
bronchoprovocation test has been previously re-
ported,21 these challenges to S. commune had been
carried out carefully with a diluted extract based on
the skin test titration. When future studies clarify the
reliability of some allergological makers as a substitu-
tion for the inhalation test which is not commonly
used in most clinics, the difficulties associated with
diagnosing Sc-ABPM may be resolved.
Secondly, a primary lesion underlying the Sc-
ABPM was considered with regard to the clinical
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manifestations demonstrated in our cases. Although a
recent pathological study revealed the presence of
mucus plugs to be the primary lesion related to
ABPA,22 this MIB theory does not sufficiently eluci-
date the mechanisms of the clinical manifestations
which were demonstrated in Case 2 either upon ad-
mission or environmental exposure.
Both cases presented with eosinophilic bronchitis,
but no asthmatic conditions were observed. The exis-
tence of mucoid impaction depends on the character-
istics of mucus production of each fungus which colo-
nized in the bronchial walls. Continuous inflamma-
tion caused by protease products released by intra-
mucus fungi will lead to central bronchiectasis.
Therefore, clinical manifestations such as asthma,
mucoid impaction, and central bronchiectasis are im-
portant when considering the differential diagnosis of
such disease, but they are not definitive Sc-ABPM
symptoms.
We therefore hypothesized that the allergic reac-
tion such as eosinophilic bronchoalveolitis spreading
around the mucus plug was the fundamental condi-
tion as a primary lesion underlying the Sc-ABPM23
based on the assumption that the host was afebrile
when allergic reactions induced by S. commune are
limited to the bronchus area, and these patients tend
to become febrile while, on the other hand, their
chest radiographs demonstrate consolidations in the
lung fields when allergic reactions reach the alveolar
area.
This proposed concept of a primary lesion in this
disease may elucidate the mechanism of the positive
response demonstrated in the bronchoprovocation
tests in not only case 2, but also in case 1, which was
afebrile, and it enabled two cases of MIB that demon-
strated quite different clinical manifestations to be lo-
cated in the same spectrum of ABPM.
Finally, the successful treatment of Sc-ABPM is
herein discussed. In such a situation, the successful
treatment is assumed to consist of 4 strategies; 1) the
prevention and eradication of fungal colonization in
the airway, 2) the control of eosinophilic bronchitis
caused by fungal exposure, 3) the removal of any mu-
cus plugs from the airway, and 4) the effective man-
agement of environmental fungi.
Gonzalez GM et al. reported that S. commune was
susceptible in vitro to ITCZ, amphotericin B, and vori-
conazole, with MIC values of 0.06 μgml, 0.5 μgml
and 0.5 μgml, respectively.24 Therefore, such anti-
fungal therapy may have some advantages25 in either
reducing or eradicating such antigen exposure.26-28
Because the specimens obtained from transbronchial
bronchial biopsy showed no findings of fungal infec-
tion in the bronchial wall, it was suggested that ITCZ
therapy13,26 may be efficacious for preventing the
fungi from colonizing the airway upon antigen expo-
sure, which subsequently causes eosinophilic inflam-
mation. It was remarkable that the low dose ITCZ
therapy in case 2 successfully prevented relapse upon
environmental re-exposure28 and stopped eosinophil
movement29 (Strategy 1). For the treatment of an al-
lergic reaction in the airway which has already been
started by the colonization of the fungi, both inhaled
and oral corticosteroids are considered to be effica-
cious30 (Strategy 2). On the other hand, the oral
drugs seemed to be more difficult to deliver to the
fungus colonizing inside the mucus plug. In the near
future, the use of additional therapy, such as nebu-
lized antifungal drugs31 should be evaluated for the
treatment of the mucus plug. The utility of the bron-
choscopic suctioning and flushing as a mechanical
treatment has been reported previously2,17; and we
also experienced the efficacy of this mechanical treat-
ment (Strategy 3). S. commune is a basidiomycetous
fungus that colonizes rotting wood, and it is distrib-
uted throughout the world. It is known that the quan-
tity of antigen from the basidiomycetous fungi is af-
fected by the season.32 Our case reports suggested
that the control of the disease recurrence which
seemed to be influenced by the existence of S. com-
mune in the environment will be accomplished by the
environmental management (Strategy 4).
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